Adult dermatomyositis is a condition defined by this packet as dermatomyositis occurring in an adult. This packet does not provide certified data on prevalence, age of onset, sex distribution, or causative genes for this condition. Orphan-drug designation has been granted for at least one investigational agent targeting dermatomyositis, reflecting regulatory recognition of the condition's rarity.

Certified symptom, phenotype, and characteristic-findings data are not available in this packet. The clinical features of adult dermatomyositis are therefore not described here based on packet-certified information.

This packet does not provide a certified causative-gene claim for adult dermatomyositis. No inheritance pattern, molecular mechanism, or de novo rate is certified in this packet.

Certified diagnostic methods, testing hierarchies, biomarker thresholds, and diagnostic criteria for adult dermatomyositis are not provided in this packet. Newborn screening data are also not available.

No FDA-approved treatments or foundational therapies for adult dermatomyositis are certified in this packet. One orphan-drug designation record is present: a GLP-1/ELP-120 fusion protein developed by ImmunoForge Co., Ltd. has received orphan designation for the treatment of dermatomyositis. Orphan designation is a regulatory status distinct from FDA approval and does not indicate that this agent is approved, available, or currently under active clinical investigation. No patient assistance programs are certified in this packet.

Prognosis and natural history data for adult dermatomyositis are not certified in this packet.

Numerous certified active clinical trial records are present for adult dermatomyositis. The research landscape includes studies across multiple phases and sponsors. Notable certified trials include: a Phase 3 study (NCT05437263) sponsored by Priovant Therapeutics investigating the efficacy and safety of brepocitinib in adults with dermatomyositis (active, not recruiting; started October 2022, with a projected completion of July 2026); a Phase 3 study (NCT04972760) sponsored by Assistance Publique – Hôpitaux de Paris evaluating baricitinib in patients with relapsing or treatment-naive dermatomyositis (recruiting; started August 2022, projected completion February 2028); and a Phase 2 study (NCT06154252) sponsored by Cabaletta Bio evaluating CABA-201 in subjects with active idiopathic inflammatory myopathy or juvenile idiopathic inflammatory myopathy under the RESET-Myositis protocol (recruiting; started December 2023, projected completion July 2028). Additional certified trials address topics including biomarker identification, environmental risk factors, and mental health interventions. The packet also reflects published research activity in epidemiology and natural history, biomarkers, and recent clinical trials. Active clinical trials for this condition are listed on ClinicalTrials.gov.